Taurine zinc solid dispersions attenuate doxorubicin-induced hepatotoxicity and cardiotoxicity in rats
Description
The clinical efficacy of anthracycline anti-neoplastic agents is limited by cardiac and hepatic toxicities. The aim of this study was to assess the hepatoprotective and cardioprotective effects of taurine zinc solid dispersions, which is a newly-synthesized taurine zinc compound, against doxorubicin-induced toxicity in Sprague–Dawley rats intraperitoneally injected with doxorubicin hydrochloride (3 mg/kg) three times a week (seven injections) over 28 days. Hemodynamic parameters, levels of liver toxicity markers and oxidative stress were assessed. Taurine zinc significantly attenuated the reductions in blood pressure, left ventricular pressure and ± dp/dtmax, increases in serum alanine aminotransferase and aspartate aminotransferase activities, and reductions in serum Zn2+ and albumin levels (P < 0.05 or 0.01) induced by doxorubicin. In rats treated with doxorubicin, taurine zinc dose-dependently increased liver superoxide dismutase activity and glutathione concentration, and decreased malondialdehyde level (P < 0.01). qBase+ was used to evaluate the stability of eight candidate reference genes for real-time quantitative reverse-transcription PCR. Taurine zinc dose-dependently increased liver heme oxygenase-1 and UDP-glucuronyl transferase mRNA and protein expression (P < 0.01). Western blotting demonstrated that taurine zinc inhibited c-Jun N-terminal kinase phosphorylation by upregulating dual-specificity phosphoprotein phosphatase-1. Additionally, taurine zinc inhibited cardiomyocyte apoptosis as there was decreased TUNEL/DAPI positivity and protein expression of caspase-3. These results indicate that taurine zinc solid dispersions prevent the side-effects of anthracycline-based anticancer therapy. The mechanisms might be associated with the enhancement of antioxidant defense system partly through activating transcription to synthesize endogenous phase II medicine enzymes and anti-apoptosis through inhibiting JNK phosphorylation. - Highlights: • Dissolution of taurine zinc complex can be increased by solid dispersions (SDs). • Taurine zinc SDs blocked doxorubicin-induced hepatotoxicity and cardiotoxicity. • Taurine zinc SDs can alleviate oxidative stress and dampen JNK phosphorylation. • Taurine zinc SDs increased the expression of UGT, HO-1 at mRNA and protein level. • Taurine zinc SDs revealed greater hepatoprotective effects than silymarin.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.taap.2015.08.017Additional details
Identifiers
- DOI
- 10.1016/j.taap.2015.08.017;
- PII
- S0041-008X(15)30069-7;
Publishing Information
- Journal Title
- Toxicology and Applied Pharmacology
- Journal Volume
- 289
- Journal Issue
- 1
- Journal Page Range
- p. 1-11
- ISSN
- 0041-008X
- CODEN
- TXAPA9
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 49036814
- Subject category
- S60: APPLIED LIFE SCIENCES;
- Descriptors DEI
- ALANINES; ALBUMINS; APOPTOSIS; DEOXYURIDINE; DOXORUBICIN; GLUTATHIONE; HEME; LIVER; MESSENGER-RNA; OXYGENASES; PHOSPHATASES; PHOSPHOPROTEINS; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; RATS; SUPEROXIDE DISMUTASE; TAURINE; THERAPY; TOXICITY; ZINC
- Descriptors DEC
- AMINES; AMINO ACIDS; ANIMALS; ANTIBIOTICS; ANTI-INFECTIVE AGENTS; ANTIMETABOLITES; ANTINEOPLASTIC DRUGS; AZINES; BODY; CARBOXYLIC ACIDS; CHEMICAL REACTIONS; DIGESTIVE SYSTEM; DRUGS; ELEMENTS; ENZYMES; ESTERASES; GENE AMPLIFICATION; GLANDS; HETEROCYCLIC ACIDS; HETEROCYCLIC COMPOUNDS; HYDROLASES; HYDROXY COMPOUNDS; MAMMALS; MEDICINE; METALS; NUCLEIC ACIDS; NUCLEOSIDES; NUCLEOTIDES; ORGANIC ACIDS; ORGANIC COMPOUNDS; ORGANIC NITROGEN COMPOUNDS; ORGANIC SULFUR COMPOUNDS; ORGANS; OXIDOREDUCTASES; PEPTIDES; PIGMENTS; POLYPEPTIDES; PORPHYRINS; PROTEINS; PYRIMIDINES; RADIOPROTECTIVE SUBSTANCES; RESPONSE MODIFYING FACTORS; RIBOSIDES; RNA; RODENTS; SULFONIC ACIDS; URACILS; VERTEBRATES
Optional Information
- Copyright
- Copyright (c) 2015 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.